Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021

Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021




Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021

NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) — Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that management is scheduled to deliver a company presentation at BTIG Virtual Biotechnology Conference 2021 on Monday, August 9th at 9:00 am ET. The team will also host one-on-one investor meetings throughout the conference.

Per Hellsund, President and CEO of Cybrexa, will provide an overview of CBX-12 (alphalex™-exatecan), the company’s lead therapeutic candidate for solid tumors, and the recently initiated Phase 1/2 trial in patients with advanced or metastatic refractory solid tumors. CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™. In contrast to these ADCs, CBX-12 is able to target cancer cells independent of antigen expression, which could greatly expand the addressable patient populations.

About the alphalex™ Technology Platform
The Cybrexa alphalex™ technology platform – which consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent (payload) – enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. View a video of the mechanism of action of the technology at www.cybrexa.com. 

About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, has entered a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit www.cybrexa.com.

Contacts

Cybrexa Therapeutics
Lisa Rehm
Email: lisa.rehm@cybrexa.com

Westwicke, an ICR Company
Investor Relations                                                                                
Stephanie Carrington
Tel: 646-277-1282
Email: Stephanie.Carrington@westwicke.com

Media Relations
Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@westwicke.com